SAGAseq - ultrasensitive cancer liquid biopsy sequencing
| Reference number | |
| Coordinator | SAGA Diagnostics AB |
| Funding from Vinnova | SEK 2 000 000 |
| Project duration | March 2021 - December 2022 |
| Status | Completed |
| Venture | Innovation projects in enterprises |
| Call | Innovation projects in SMEs 2020 |
Important results from the project
Aim: develop ultrasensitive and cancer-specific panels in order to improve monitoring. Fulfilment: An ultrasensitive combination product.
Expected long term effects
Our method can be used to track MRD and find relapses in different cancer types. This has created a big interest among KOLs.
Approach and implementation
Plan vs reality: Our execution suffered due to Covid, moreover the market needs changed during the course of the project which led to pivoting.